Trial Profile
A Phase I Study of AC220 for Children with Relapsed or Refractory ALL or AML (IND 111461)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary) ; Cytarabine; Etoposide; Methotrexate
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms TACL
- 26 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 13 Aug 2013 Final results will be presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2013, according to an Ambit Biosciences media release.